loading...| Preferred Name |
Gemtuzumab Ozogamicin |
|
| Synonyms |
Gemtuzumab Ozogamicin gemtuzumab ozogamicin WAY-CMA-676 Gemtuzumab ozogamicin GEMTUZUMAB OZOGAMICIN Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody hP67.6-Calicheamicin CDP-771 CMA-676 Mylotarg gemtuzumab |
|
| Definitions |
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1806 |
|
| Accepted_Therapeutic_Use_For |
Acute Myeloid Leukemia. |
|
| ALT_DEFINITION |
A monoclonal antibody combined with a toxic substance that is used to treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Mylotarg is a type of antibody-drug conjugate. |
|
| CAS_Registry |
220578-59-6 |
|
| Chemical_Formula |
C73H96IN6O25S3 |
|
| code |
C1806 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173234 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C174019 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc PCDC |
|
| DEFINITION |
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04) |
|
| Display_Name |
Gemtuzumab Ozogamicin |
|
| FDA_UNII_Code |
8GZG754X6M |
|
| FULL_SYN |
Gemtuzumab Ozogamicin gemtuzumab ozogamicin WAY-CMA-676 Gemtuzumab ozogamicin GEMTUZUMAB OZOGAMICIN Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody hP67.6-Calicheamicin CDP-771 CMA-676 Mylotarg gemtuzumab |
|
| Has_Target | ||
| Is_PCDC_AML_Authorized_Value_For_Variable | ||
| Is_Value_For_GDC_Property | ||
| label |
Gemtuzumab Ozogamicin |
|
| Legacy Concept Name |
Gemtuzumab_Ozogamicin |
|
| Maps_To |
Gemtuzumab Ozogamicin |
|
| NCI_Drug_Dictionary_ID |
42868 |
|
| NSC Number |
720568 |
|
| PDQ_Closed_Trial_Search_ID |
42868 |
|
| PDQ_Open_Trial_Search_ID |
42868 |
|
| Preferred_Name |
Gemtuzumab Ozogamicin |
|
| prefixIRI |
Thesaurus:C1806 |
|
| Semantic_Type |
Pharmacologic Substance Immunologic Factor |
|
| UMLS_CUI |
C1533699 |
|
| subClassOf |